Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Acquisitions (2019)

Lineage Cell Therapeutics' Acquisitions history spans 4 years, with the latest figure at $3.1 million for Q1 2019.

  • For Q1 2019, Acquisitions changed N/A year-over-year to $3.1 million; the TTM value through Dec 2019 reached $3.1 million, changed N/A, while the annual FY2019 figure was $3.1 million, N/A changed from the prior year.
  • Acquisitions reached $3.1 million in Q1 2019 per LCTX's latest filing, up from $292387.0 in the prior quarter.
  • In the past five years, Acquisitions ranged from a high of $3.1 million in Q1 2019 to a low of $3.1 million in Q1 2019.